QSVLTQPPSLSVAPGKTATFTCGGNNIGDKSVHWYRQKPGQAPVLVMYLDT ERPSGIPERMSGSNFGNTATLTITRVEAGDEADYYCQVWDSGSDHVVFGGGT KLTVLG (SEQ ID NO 8).

3. The compound of Claim 2, wherein the cell binding agent further comprises: a light chain comprising the amino acid sequence of SEQ ID NO: 10; and a heavy chain comprising the amino acid sequence of SEQ ID NO: 9.

4. The compound of Claim 3, wherein the cell binding agent further comprises: two light chains each comprising the amino acid sequence of SEQ ID NO: 10; and two heavy chains each comprising the amino acid sequence of SEQ ID NO: 9.

5. The compound of Claims 1-4, ~~with a drug-to-antibody ratio of~~ wherein n is 2.0 to 5.0.

6. The compound of Claims 1-4, ~~with a drug-to-antibody ratio of~~ wherein n is 3.5 ± 0.5.

7. A pharmaceutical composition comprising the compound of any one of Claims 1-6 together with a pharmaceutically acceptable carrier, diluent or excipient.

8. The pharmaceutical composition of Claim 7 further comprising an additional pharmaceutical agent.

9. The compound of any one of Claims 1-6 for use in therapy.

10. The compound of any one of Claims 1-6 for use in treating cancer.

11. The compound of any one of Claims 1-6 for use in treating cancer in a patient having a level of FGFR3 expression that is greater than the level of FGFR3 expression in a control population.

12. The compound of any one of Claims 1-6 for use according to Claim 11, wherein the control population comprises at least one individual not suffering from cancer.

13. The compound of any one of Claims 1-6 for use in treating cancer in a patient having:

(a) a mutation of FGFR3 (SEQ ID NO 11), wherein the mutation is selected from the group consisting of S249C, R248C, Y373C, Y375C, and combinations thereof;

(b) a fusion of FGFR3-TACC3; or

(c) a combination of (a) and (b).

14. The compound of any one of Claims 1-6 for use in treating cancer in a patient having:

(a) a mutation of FGFR3 (SEQ ID NO 11), wherein the mutation is selected from the group consisting of S249C, R248C, Y373C, Y375C, and combinations thereof;

(b) a fusion of FGFR3-TACC3; or

(c) a combination of (a) and (b),

wherein the treatment comprises determining whether or not the patient has (a) a mutation of FGFR3 (SEQ ID NO 11), wherein the mutation is selected from the group consisting of S249C, R248C, Y373C, Y375C, and combinations thereof; (b) a fusion of FGFR3-TACC3; or (c) a combination of (a) and (b), by *ex vivo* or *in vitro* determining the presence of (i) one or more of the S249C, R248C, Y373C, Y375C mutations; (ii) a fusion of FGFR3-TACC3; or (iii) a combination of (i) and (ii) in a biological sample of the patient.

15. The compound of any one of Claims 1-6 for use according to any one of Claims 10-14, wherein the cancer is bladder cancer or multiple myeloma.

16. The compound of any one of Claims 1-6 for use according to any one of Claims 10-15, wherein said compound is administered simultaneously, separately or sequentially with another anti-cancer treatment.

17. The compound of any one of Claims 1-6 for use according to Claim 16, wherein said anti-cancer treatment is selected from the group consisting of an anti-angiogenic agent, a chemotherapeutic agent, and an anti-neoplastic agent.

18. The compound of any one of Claims 1-6 for use according to Claim 17, wherein said anti-neoplastic agent is cisplatin.

~~19. A method of treating cancer in a mammal, comprising administering to said mammal in need thereof the compound of Claims 1-6 wherein the cancer is selected from the group consisting of bladder cancer or multiple myeloma.~~

~~20. The method of Claim 19, further comprising administering another anti-cancer treatment to said mammal wherein said anti-cancer treatment is selected from the group consisting of an anti-angiogenic agent, a chemotherapeutic agent, and an anti-neoplastic agent.~~

~~21. The method of Claim 20, wherein said anti-neoplastic agent is cisplatin.~~

~~22. A method of treating cancer in a patient, comprising the steps:~~

~~(a) measuring the expression level of FGFR3 (SEQ ID NO 11) in a sample taken from the patient wherein the sample is selected from the group consisting of blood, serum, plasma, urine, and tissue; and~~

~~(b) administering to the patient the compound according to any one of Claims 1-6 if the FGFR3 expression level is above the FGFR3 expression level found in a control population.~~

~~23. A method of treating cancer in a patient, comprising the steps:~~

~~(a) determining the presence of an anomaly in a sample taken from the patient, wherein the anomaly is:~~

~~(1) a mutation of FGFR3 (SEQ ID NO 11), wherein the mutation is selected from the group consisting of S249C, R248C, Y373C, Y375C, and combinations thereof;~~

~~(2) a fusion of FGFR3-TACC3; or~~

~~(3) a combination of (1) and (2),~~

~~and wherein the sample is selected from the group consisting of blood, serum, plasma, urine, tissue, tumor cells, tumor tissue samples, circulating tumor cells, and circulating DNA, and~~

~~(b) administering to the patient the compound according to any one of Claims 1-6 if the anomaly is present.~~

19. Use of the compound of any one of Claims 1-6 in the manufacture of a medicament for the treatment of cancer in a patient.

20. The use of Claim 19, wherein the patient has a level of FGFR3 expression that is greater than the level of FGFR3 expression in a control population.

21. The use of Claim 20, wherein the control population comprises at least one individual not suffering from cancer.

22. The use of Claim 19, wherein the patient has:

(a) a mutation of FGFR3 (SEQ ID NO 11), wherein the mutation is selected from the group consisting of S249C, R248C, Y373C, Y375C, and combinations thereof;

(b) a fusion of FGFR3-TACC3; or

(c) a combination of (a) and (b).

23. The use of Claim 19, wherein the patient has:

(a) a mutation of FGFR3 (SEQ ID NO 11), wherein the mutation is selected from the group consisting of S249C, R248C, Y373C, Y375C, and combinations thereof;

(b) a fusion of FGFR3-TACC3; or

(c) a combination of (a) and (b),

wherein the treatment comprises determining whether or not the patient has (a) a mutation of FGFR3 (SEQ ID NO 11), wherein the mutation is selected from the group consisting of S249C, R248C, Y373C, Y375C, and combinations thereof; (b) a fusion of FGFR3-TACC3; or (c) a combination of (a) and (b), by *ex vivo* or *in vitro* determining the presence of (i) one or more of the S249C, R248C, Y373C, Y375C mutations; (ii) a fusion of FGFR3-TACC3; or (iii) a combination of (i) and (ii) in a biological sample of the patient.

24. The use of Claims 19-23, wherein the cancer is bladder cancer or multiple myeloma.

25. The use of Claims 19-24, wherein said compound is to be administered simultaneously, separately or sequentially with another anti-cancer treatment.

26. The use of Claim 25, wherein said anti-cancer treatment is selected from the group consisting of an anti-angiogenic agent, a chemotherapeutic agent, and an anti-neoplastic agent.

27. The use of Claim 26, wherein said anti-neoplastic agent is cisplatin.

~~24~~28. A method for determining whether a subject having a cancer is a candidate for the compound of Claims 1-6, comprising: *ex vivo* or *in vitro* determining the level of FGFR3 (SEQ ID NO 11) expression in a sample of the subject, wherein the sample is selected from the group consisting of blood, serum, plasma, urine, and tissue, wherein an increase in the level of FGFR3 expression, as compared with the level of FGFR3 expression in an individual not suffering from cancer, is indicative that the subject is a candidate for the compound.

~~25~~29. A method for determining whether a subject having a cancer is a candidate for the compound of Claims 1-6, comprising:

(a) *ex vivo* or *in vitro* determining the presence of an anomaly in a sample taken from a patient, wherein the anomaly is:

(1) a mutation of FGFR3 (SEQ ID NO 11) wherein the mutation is selected from the group consisting of S249C, R248C, Y373C, Y375C, and combinations thereof;

(2) a fusion of FGFR3-TACC3; or

(3) a combination of (1) or (2); and

(b) wherein the sample is selected from the group consisting of blood, serum, plasma, urine, tissue, tumor cells, tumor tissue samples, circulating tumor cells, and circulating DNA.